Recent IPO Insys Therapeutics soars after posting a solid Q2

Recent IPO Insys Therapeutics (INSY +23%) posts its first earnings report since its debut, easily topping Q2 estimates as revenue nearly doubled from the previous quarter.

Subsys generated $18.5M in net revenue, up 90.8% Q/Q from $9.7M in Q1.

Gross margin was 86%, compared to 34% for Q212, primarily a result of a big jump in sales of Subsys which has a higher gross margin than Dronabinol.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs